Oncological treatment software developer Ziliomics has raised an undisclosed sum from Fight Against Cancer Innovation Trust, a commercialisation partner of OICR.

Ziliomics, a Canada-based oncological treatment software spinout of commercialisation unit Fight Against Cancer Innovation Trust (Facit), obtained an undisclosed amount of seed financing yesterday from Facit’s Prospects Oncology Fund.

Facit is the commercialisation partner of the Ontario Institute for Cancer Research (OICR), whose informatics and genomics experts came up with the idea behind Ziliomics.

Prospects Oncology Fund launched in March 2017 to drive Ontario-based oncological projects through the proof-of-concept stage towards further investment.

Ziliomics is developing biomedical data analytics software that…